ZMB Member Dirk Schadendorf
ZMB Member
Dirk Schadendorf
Next ZMB-Member
Prof. Dr. Dirk Schadendorf
Director of:
Clinic for Dermatology
University Hospital Essen
Hufelandstraße 55
45147 Essen
- +49 201 723 4342
- Website
- Selected Publications
-
- Publication Metrics
- ZMB Research Program
Oncology
Research Overview
- Malignant melanoma
- Merkel cell carcinoma
- Squamous cell carcinoma
- Basal cell carcinoma
- Mycosis Fungoides/Sezary syndrome (T-Zell-Non-Hodgkin-Lymphoma)
- Application observation
Selected Publications
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialIn: The Lancet Oncology Vol. 22 (2021) Nr. 5, pp. 643 - 654
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialIn: The Lancet Oncology Vol. 22 (2021) Nr. 5, pp. 655 - 664
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib : A clinical validation studyIn: The Lancet Oncology Vol. 22 (2021) Nr. 3, pp. 370 - 380
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumoursIn: Annals of Oncology Vol. 32 (2021) Nr. 11, pp. 1332 - 1347
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasionIn: Nature Genetics Vol. 53 (2021) Nr. 3, pp. 332 - 341
ISSN: 1061-4036; 1546-1718Online Full Text: dx.doi.org/; Online Full Text: dx.doi.org/ (Open Access) -
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV⁶⁰⁰-mutant, stage III melanoma (COMBI-AD) : Exploratory biomarker analyses from a randomised, phase 3 trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 3, pp. 358 - 372
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : a randomised, double-blind, placebo-controlled, phase 2 trialIn: The Lancet Vol. 395 (2020) Nr. 10236, pp. 1558 - 1568
ISSN: 1474-547X; 0140-6736Online Full Text: dx.doi.org/ -
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical TrialIn: JAMA Oncology Vol. 6 (2020) Nr. 4, pp. 519 - 527
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ (Open Access) -
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma : Pooled Analysis of 3 Clinical TrialsIn: JAMA Oncology Vol. 6 (2020) Nr. 8, pp. 1256 - 1264
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ (Open Access) -
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Vol. 26 (2020) Nr. 7, pp. 1147
ISSN: 1546-170X; 1078-8956Online Full Text: dx.doi.org/ (Open Access) -
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samplesIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 6232
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Vol. 580 (2020) Nr. 7801, pp. E1
ISSN: 1476-4687; 0028-0836Online Full Text: dx.doi.org/ (Open Access) -
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumoursIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 1335
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Cemiplimab in locally advanced cutaneous squamous cell carcinoma : results from an open-label, phase 2, single-arm trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 2, pp. 294 - 305
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-iIn: Nature Medicine Vol. 26 (2020) Nr. 10, pp. 1557 - 1563
ISSN: 1546-170X; 1078-8956Online Full Text: dx.doi.org/ -
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Vol. 31 (2020) Nr. 1, pp. 144 - 152
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibilityIn: Nature Genetics Vol. 52 (2020) Nr. 5, pp. 494 - 504
ISSN: 1061-4036; 1546-1718Online Full Text: dx.doi.org/ -
Integrated molecular drivers coordinate biological and clinical states in melanomaIn: Nature Genetics Vol. 52 (2020) Nr. 12, pp. 1373 - 1383
ISSN: 1061-4036; 1546-1718Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Metabolic heterogeneity confers differences in melanoma metastatic potentialIn: Nature Vol. 577 (2020) Nr. 7788, pp. 115 - 120
ISSN: 1476-4687; 0028-0836Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Pan-cancer analysis of whole genomesIn: Nature Vol. 578 (2020) Nr. 7793, pp. 82 - 93
ISSN: 0028-0836; 1476-4687Online Full Text: dx.doi.org/ (Open Access) -
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv⁶⁰⁰ mutation–positive melanoma receiving adjuvant vemurafenibIn: Annals of Oncology Vol. 31 (2020) Nr. 1, pp. 153 - 159
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Rationale for Immune Checkpoint Inhibitors plus Targeted Therapy in Metastatic Melanoma : A ReviewIn: JAMA Oncology Vol. 6 (2020) Nr. 12, pp. 1957 - 1966
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ -
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samplesIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 4748
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Sex differences in oncogenic mutational processesIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 4330
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Vol. 577 (2020) Nr. 7791, pp. 561 - 565
ISSN: 0028-0836; 1476-4687Online Full Text: dx.doi.org/ -
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Vol. 25 (2019) Nr. 12, pp. 1916 - 1927
ISSN: 1546-170X; 1078-8956Online Full Text: dx.doi.org/ (Open Access) -
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL) : a multicentre, open-label, randomised, controlled phase II trialIn: Annals of Oncology Vol. 30 (2019) Nr. 2, pp. 317 - 324
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) : a randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Vol. 20 (2019) Nr. 5, pp. 701 - 710
ISSN: 1474-5488Online Full Text: dx.doi.org/ -
Publisher Correction : Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Vol. 10 (2019) Nr. 1, pp. 299
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Vol. 10 (2019) Nr. 1, pp. 299
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy : Three-Year Follow-up of a Randomized Phase 3 TrialIn: JAMA Oncology Vol. 5 (2019) Nr. 2, pp. 187 - 194
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ (Open Access) -
Treatment in metastatic melanoma : Time to re-thinkIn: Annals of Oncology Vol. 30 (2019) Nr. 4, pp. 501 - 503
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeIn: Cell Vol. 175 (2018) Nr. 4, pp. 984 - 997.e24
ISSN: 1097-4172; 0092-8674Online Full Text: dx.doi.org/ (Open Access) -
Adjuvant melanoma therapy with new drugs : should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?In: The Lancet Oncology Vol. 19 (2018) Nr. 12, pp. e720 - e725
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trialIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii446
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy : a retrospective, multicohort analysisIn: The Lancet Oncology Vol. 19 (2018) Nr. 3, pp. 310 - 322
ISSN: 1470-2045Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeIn: Cell Vol. 173 (2018) Nr. 3, pp. 624 - 633.e8
ISSN: 1097-4172; 0092-8674Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) : a multicentre, open-label, randomised phase 3 trialIn: The Lancet Oncology Vol. 19 (2018) Nr. 5, pp. 603 - 615
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/; Online Full Text: dx.doi.org/ (Open Access) -
Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii445
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsIn: Nature Genetics Vol. 50 (2018) Nr. 9, pp. 1271 - 1281
ISSN: 1061-4036; 1546-1718Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
MelanomaIn: The Lancet Vol. 392 (2018) Nr. 10151, pp. 971 - 984
ISSN: 0140-6736; 1474-547XOnline Full Text: dx.doi.org/ -
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) : 4-year outcomes of a multicentre, randomised, phase 3 trialIn: The Lancet Oncology Vol. 19 (2018) Nr. 11, pp. 1480 - 1492
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Vol. 9 (2018) Nr. 1, pp. 4774
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)In: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii735
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Vol. 19 (2018) Nr. 10, pp. 1315 - 1327
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Sebaceous tumours: more than skin deepIn: Gut Vol. 67 (2018) Nr. 11, pp. 2045 - 2053
ISSN: 0017-5749; 1468-3288Online Full Text: dx.doi.org/ -
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanomaIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii734 - viii735
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanomaIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8,
ISSN: 1569-8041; 0923-7534 -
Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesionsIn: Nature Communications Vol. 8 (2017)
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Vol. 18 (2017) Nr. 4, pp. 435 - 445
ISSN: 1470-2045Online Full Text: dx.doi.org/ -
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma : long-term survival and safety analysis of a phase 3 studyIn: Annals of Oncology Vol. 28 (2017) Nr. 7, pp. 1631 - 1639
ISSN: 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma : Final results from the global, single-arm, phase ii team trialIn: Annals of Oncology Vol. 28 (2017) Nr. 6, pp. 1380 - 1387
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trialIn: The Lancet Oncology Vol. 18 (2017) Nr. 5, pp. 611 - 622
ISSN: 1470-2045Online Full Text: dx.doi.org/ -
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression : Analysis of 2 Phase 3 Clinical TrialsIn: JAMA Oncology Vol. 3 (2017) Nr. 11, pp. 1511 - 1519
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ -
Predictors of responses to immune checkpoint blockade in advanced melanomaIn: Nature Communications Vol. 8 (2017) pp. 592
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regressionIn: Nature Communications Vol. 8 (2017) pp. 14447
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE) : a randomised, regimen-controlled, double-blind, phase 2 trialIn: The Lancet Oncology Vol. 18 (2017) Nr. 3, pp. 404 - 412
ISSN: 1470-2045Online Full Text: dx.doi.org/ -
Vemurafenib in metastatic melanoma patients with brain metastases : An open-label, single-arm, phase 2, multicentre studyIn: Annals of Oncology Vol. 28 (2017) Nr. 3, pp. 634 - 641
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanomaIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6,
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Adjuvant treatment with pegylated interferon ?-2a versus low-dose interferon ?-2a in patients with high-risk melanoma : a randomized phase III DeCOG trialIn: Annals of Oncology Vol. 27 (2016) Nr. 8, pp. 1625 - 1632
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapyIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1145P
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trialsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1140P
ISSN: 1569-8041Online Full Text: dx.doi.org/ -
Checkpoint inhibitors : a new standard of care for advanced Merkel cell carcinoma?In: The Lancet Oncology Vol. 17 (2016) Nr. 10, pp. 1337 - 1339
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE studyIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1152P
ISSN: 1569-8041Online Full Text: dx.doi.org/ -
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment : a pooled analysis of individual patient data from randomised trialsIn: The Lancet Oncology Vol. 17 (2016) Nr. 12, pp. 1743 - 1754
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Final overall survival for KEYNOTE-002 : pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanomaIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1107O
ISSN: 1569-8041Online Full Text: dx.doi.org/ -
Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanomaIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1137P
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL) : A pooled analysisIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1112PD
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trialsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1134P
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanomaIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. LBA40
ISSN: 1569-8041Online Full Text: dx.doi.org/ -
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceIn: Nature Vol. 532 (2016) Nr. 7598, pp. 250 - 254
ISSN: 0028-0836; 1476-4687Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma : pretreatment impacts survivalIn: Annals of Oncology Vol. 26 (2015) Nr. 3, pp. 573 - 582
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v) : results of a phase 3, open-label, randomised trialIn: The Lancet Oncology Vol. 16 (2015) Nr. 13, pp. 1389 - 1398
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma : a multicentre, double-blind, phase 3 randomised controlled trialIn: The Lancet Vol. 386 (2015) Nr. 9992, pp. 444 - 451
ISSN: 0140-6736; 1474-547XOnline Full Text: dx.doi.org/ -
Disease kinetics for decision-making in advanced melanoma : a call for scenario-driven strategy trialsIn: The Lancet Oncology Vol. 16 (2015) Nr. 13, pp. e522 - e526
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Expanded access programmes : patient interests versus clinical trial integrityIn: The Lancet Oncology Vol. 16 (2015) Nr. 1, pp. 15 - 17
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanomaIn: Nature Genetics Vol. 47 (2015) Nr. 9, pp. 987 - 995
ISSN: 1061-4036; 1546-1718Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Genomic Classification of Cutaneous MelanomaIn: Cell Vol. 161 (2015) Nr. 7, pp. 1681 - 1696
ISSN: 1097-4172Online Full Text: dx.doi.org/ (Open Access) -
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trialIn: The Lancet Oncology Vol. 16 (2015) Nr. 8, pp. 908 - 918
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsIn: Annals of Oncology Vol. 26 (2015) Nr. 6, pp. 1238 - 1244
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology Vol. 26 (2015) Nr. 1, pp. 250 - 251
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology Vol. 25 (2014) Nr. 3, pp. 747 - 753
ISSN: 1569-8041Online Full Text: dx.doi.org/ -
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma : Quality-of-life analyses of the METRIC studyIn: Annals of Oncology Vol. 25 (2014) Nr. 3, pp. 700 - 706
ISSN: 1569-8041Online Full Text: dx.doi.org/ -
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021) : A multicentric randomized trialIn: Annals of Oncology Vol. 25 (2014) Nr. 3, pp. 742 - 746
ISSN: 1569-8041Online Full Text: dx.doi.org/ -
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3) : extended follow-up of a phase 3, randomised, open-label studyIn: The Lancet Oncology Vol. 15 (2014) Nr. 3, pp. 323 - 332
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trialsIn: The Lancet Oncology Vol. 15 (2014) Nr. 3, pp. 297 - 304
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanomaIn: Nature Vol. 507 (2014) Nr. 7490, pp. 109 - 113
ISSN: 0028-0836; 1476-4687Online Full Text: dx.doi.org/ -
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 studyIn: The Lancet Oncology Vol. 14 (2013) Nr. 3, pp. 249 - 256
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma : A phase 2 double-blind randomised studyIn: The Lancet Oncology Vol. 14 (2013) Nr. 8, pp. 733 - 740
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
A Landscape of Driver Mutations in MelanomaIn: Cell Vol. 150 (2012) Nr. 2, pp. 251 - 263
ISSN: 0092-8674; 1097-4172Online Full Text: dx.doi.org/ -
Advances and perspectives in immunotherapy of melanomaIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 10, pp. x104 - x108
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ Online Full Text -
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB) : A multicentre, open-label, phase 2 trialIn: The Lancet Oncology Vol. 13 (2012) Nr. 11, pp. 1087 - 1095
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/ -
Melanoma genome sequencing reveals frequent PREX2 mutationsIn: Nature Vol. 485 (2012) Nr. 7399, pp. 502 - 506
ISSN: 0028-0836; 1476-4687Online Full Text: dx.doi.org/ -
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma : A multicenter phase II DeCOG trialIn: Annals of Oncology Vol. 22 (2011) Nr. 7, pp. 1667 - 1674
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Ipilimumab monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging studyIn: The Lancet Oncology Vol. 11 (2010) Nr. 2, pp. 155 - 164
ISSN: 1470-2045; 1474-5488Online Full Text: dx.doi.org/